

**Amendment To The Claims**

Claims 1-10 (Cancelled)

11. (Currently Amended) A method for inhibiting TNF- $\alpha$  release from macrophages comprising the step of contacting said macrophages with an effective amount of an  $\alpha_d$  monoclonal antibody immunospecific for an  $\alpha_d$  polypeptide

wherein said  $\alpha_d$  polypeptide is encoded by a polynucleotide selected from the group consisting of:

- a) SEQ ID NO: 1;
  - b) a polynucleotide that encodes the polypeptide of SEQ ID NO: 2; and
  - c) a polynucleotide that hybridizes to the complement of the polynucleotide of (a) or (b), under conditions that include a final wash in 1X SSC/0.1% SDS at 65° C<sub>2</sub>
- and wherein said  $\alpha_d$  polypeptide retains a biological activity of  $\alpha_d$ .

12. (Currently Amended) A method for inhibiting TNF- $\alpha$  release from splenic phagocytes comprising the step of contacting said phagocytes with an effective amount of an  $\alpha_d$  monoclonal antibody immunospecific for an  $\alpha_d$  polypeptide

wherein said  $\alpha_d$  polypeptide is encoded by a polynucleotide selected from the group consisting of:

- a) SEQ ID NO: 1;
  - b) a polynucleotide that encodes the polypeptide of SEQ ID NO: 2; and
  - c) a polynucleotide that hybridizes to the complement of the polynucleotide of (a) or (b), under conditions that include a final wash in 1X SSC/0.1% SDS at 65° C<sub>2</sub>
- and wherein said  $\alpha_d$  polypeptide retains a biological activity of  $\alpha_d$ .

13. (Cancelled)

14. (Previously Amended) The method according to claim 13 wherein the immunospecific anti- $\alpha_d$  monoclonal antibody is specific for the  $\alpha_d$  I-domain region.